Discussion paper on pan-tumour biomarker testing to determine eligibility for targeted treatment.

Morona, J, Wyndham, A, Scott, P, Mitchell, A, Merlin, T
Record ID 32018000644
English
Authors' objectives: To provide guidance on the evidence needed to evaluate immunohistochemistry (IHC) testing for mismatch repair deficiency (dMMR) in colorectal cancer (CRC) and many other types of tumour (pan-tumour or tumour agnostic), in order to access pembrolizumab treatment. Subsequent co-dependent technology submissions seeking subsidy for biomarker testing for treatments that have pan-tumour effects may also be assessed according to this guidance.
Details
Project Status: Completed
Year Published: 2020
English language abstract: An English language summary is available
Publication Type: Other
Country: Australia
MeSH Terms
  • Biomarkers, Tumor
  • Immunohistochemistry
Keywords
  • pan-tumour
  • tumour agnostic
  • colorectal cancer
  • pembrolizumab
Contact
Organisation Name: Adelaide Health Technology Assessment
Contact Address: School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name: ahta@adelaide.edu.au
Contact Email: ahta@adelaide.edu.au
Copyright: Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.